No. 24A652
Hikma Pharmaceuticals USA Inc., et al. v. Amarin Pharma, Inc., et al.
Tags: generic-drug hatch-waxman-act induced-infringement patent-infringement section-viii skinny-label
Latest Conference:
N/A
Question Presented (AI Summary)
Whether a generic drug manufacturer can be held liable for induced patent infringement when its label complies with the Hatch-Waxman Act's 'skinny label' requirements but its public statements allegedly suggest broader use of the drug
Docket Entries
2025-01-03
Application (24A652) granted by The Chief Justice extending the time to file until February 14, 2025.
2024-12-27
Application (24A652) to extend the time to file a petition for a writ of certiorari from January 15, 2025 to February 14, 2025, submitted to The Chief Justice.
Attorneys
Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals PLC
Charles Bennett Klein — Winston & Strawn LLP, Petitioner
Charles Bennett Klein — Winston & Strawn LLP, Petitioner